Kathmandu

Govt of Nepal approves China's Vero Cell vaccine for emergency use against Covid-19

By THT ONLINE

File Photo - Department of Drug Administration in Babarmahal, Kathmandu. Photo: Nishant Pokhrel/THT Online

KATHMANDU, FEBRUARY 18

The government has approved the 'Vero Cell' vaccine manufactured by Beijing Institute of Biological Products Co Ltd (BIBP), China, under Sinopharm, for emergency use against Covid-19 in Nepal.

The Department of Drug Administration (DDA), under the Ministry of Health and Population, took a decision on the usage of the SARS-CoV-2 vaccine, Inactivated, on Wednesday.

Each 0.5 ml vaccine solution for injection contains 6.5 U of inactivated SARS-CoV-2 antigen. The route of vaccine administration is intramuscular.

Earlier last month, first phase of Covid-19 vaccination drive began in Nepal, following the arrival of vaccines from India, through Indian government's Vaccine Maitri programme. India had sent 1 million doses of Covishield vaccine to Nepal, in grant. Covishield is the local name for the India-manufactured Oxford-AstraZeneca vaccine developed in the UK.